GSK to buy Rapt in $2.2B deal for food allergy drug
GSK to buy Rapt in $2.2B deal for food allergy drug
Contenu indisponible. Consultez la source originale.
GSK to buy Rapt in $2.2B deal for food allergy drug
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.